In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age

Maria Suprun; Henry T. Bahnson; George du Toit; Gideon Lack; Mayte Suarez-Farinas; Hugh A. Sampson

doi:10.1111/all.15572

In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age

Maria Suprun, Henry T. Bahnson, George du Toit, Gideon Lack, Mayte Suarez-Farinas, Hugh A. Sampson

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English
Pages (from-to)	586-589
Number of pages	4
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	78
Issue number	2
DOIs	https://doi.org/10.1111/all.15572
State	Published - Feb 2023

Access to Document

10.1111/all.15572

Cite this

@article{2f6dbcd65844482aaf0f1ad88a394d40,

title = "In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age",

author = "Maria Suprun and Bahnson, {Henry T.} and {du Toit}, George and Gideon Lack and Mayte Suarez-Farinas and Sampson, {Hugh A.}",

note = "Funding Information: This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565, NO1‐AI‐15416, UM1AI109565, HHSN272200800029C, and UM2AI117870; the David H. and Julia Koch Research Program in Food Allergy Therapeutics; and AllerGenis LLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Dr. Suprun receives research support from NIH-NIAD (UCSD U19 AI070535-16) and has provisional patent application for egg-BBEA, this technology is filed through Mount Sinai and licensed to AllerGenis, LLC. Henry Bahnson has received research support from the NIAID/National Institutes of Health (contract nos. HHSN272200800029C and UM2AI117870) and reports contract work paid to institution, Benaroya Research Institute, from DBV Technologies, MYOR https://www.myorcare.com/, King's College London, and Stanford University; and additional salary support paid by King's College London and Stanford University. Funding Information: Dr. Suprun receives research support from NIH‐NIAD (UCSD U19 AI070535‐16) and has provisional patent application for egg‐BBEA, this technology is filed through Mount Sinai and licensed to AllerGenis, LLC. Henry Bahnson has received research support from the NIAID/National Institutes of Health (contract nos. HHSN272200800029C and UM2AI117870) and reports contract work paid to institution, Benaroya Research Institute, from DBV Technologies, MYOR https://www.myorcare.com/ , King's College London, and Stanford University; and additional salary support paid by King's College London and Stanford University. Dr. du Toit has received research support from the NIAID (NO1‐AI‐15416 [contract] and UM1AI109565 [grant], covering salary) and the UK Food Standards Agency; has received a contribution to NIAID contract/grant from the Food Allergy Research & Education; has received a contribution to KCL Division of Asthma Allergy &Lung Biology from Medical Research Council (MRC) & Asthma UK Centre; has received the Biomedical Research Centre (BRC) award to Guy's and St Thomas' National Health Service (NHS) Foundation from the UK Department of Health through the National Institute for Health Research (NIHR); and has received support for pediatric allergy clinical trial's unit from the National Peanut Board. Dr. Lack has received research support from the NIAID (NO1‐AI‐15416 [contract] and UM1AI109565 [grant]), and UK Food Standards Agency; is on the DBV Technologies scientific advisory board; has received a contribution to NIAID contract/grant from Food Allergy Research and Education; has received a contribution to KCL Division of Asthma Allergy & Lung Biology from MRC & Asthma UK Centre; has received the BRC award to Guy's and St Thomas' NHS Foundation from the UK Department of Health through NIHR; has received support for pediatric allergy clinical trial's unit from the National Peanut Board; has received discounted Bamba peanut snack from Osem; and has stock/stock options in DBV Technologies. Dr. Su{\'a}rez‐Fari{\~n}as received research funding to Mount Sinai by a grant from AllerGenis LLC. Dr. Sampson reports non‐financial support from AllerGenis LLC during the conduct of the study; grants from Immune Tolerance Network; NIAID/NIH, personal fees from N‐Fold Therapeutics, other from DBV Technologies (employee: part‐time CSO), outside the submitted work; Mount Sinai has licensed the BBEA technology to AllerGenis LLC. Dr. Sampson. serves as an unpaid Board of Directors member and advisor to AllerGenis LLC.",

year = "2023",

month = feb,

doi = "10.1111/all.15572",

language = "English",

volume = "78",

pages = "586--589",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "2",

}

TY - JOUR

T1 - In children with eczema, expansion of epitope-specific IgE is associated with peanut allergy at 5 years of age

AU - Suprun, Maria

AU - Bahnson, Henry T.

AU - du Toit, George

AU - Lack, Gideon

AU - Suarez-Farinas, Mayte

AU - Sampson, Hugh A.

N1 - Funding Information: This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565, NO1‐AI‐15416, UM1AI109565, HHSN272200800029C, and UM2AI117870; the David H. and Julia Koch Research Program in Food Allergy Therapeutics; and AllerGenis LLC. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Dr. Suprun receives research support from NIH-NIAD (UCSD U19 AI070535-16) and has provisional patent application for egg-BBEA, this technology is filed through Mount Sinai and licensed to AllerGenis, LLC. Henry Bahnson has received research support from the NIAID/National Institutes of Health (contract nos. HHSN272200800029C and UM2AI117870) and reports contract work paid to institution, Benaroya Research Institute, from DBV Technologies, MYOR https://www.myorcare.com/, King's College London, and Stanford University; and additional salary support paid by King's College London and Stanford University. Funding Information: Dr. Suprun receives research support from NIH‐NIAD (UCSD U19 AI070535‐16) and has provisional patent application for egg‐BBEA, this technology is filed through Mount Sinai and licensed to AllerGenis, LLC. Henry Bahnson has received research support from the NIAID/National Institutes of Health (contract nos. HHSN272200800029C and UM2AI117870) and reports contract work paid to institution, Benaroya Research Institute, from DBV Technologies, MYOR https://www.myorcare.com/ , King's College London, and Stanford University; and additional salary support paid by King's College London and Stanford University. Dr. du Toit has received research support from the NIAID (NO1‐AI‐15416 [contract] and UM1AI109565 [grant], covering salary) and the UK Food Standards Agency; has received a contribution to NIAID contract/grant from the Food Allergy Research & Education; has received a contribution to KCL Division of Asthma Allergy &Lung Biology from Medical Research Council (MRC) & Asthma UK Centre; has received the Biomedical Research Centre (BRC) award to Guy's and St Thomas' National Health Service (NHS) Foundation from the UK Department of Health through the National Institute for Health Research (NIHR); and has received support for pediatric allergy clinical trial's unit from the National Peanut Board. Dr. Lack has received research support from the NIAID (NO1‐AI‐15416 [contract] and UM1AI109565 [grant]), and UK Food Standards Agency; is on the DBV Technologies scientific advisory board; has received a contribution to NIAID contract/grant from Food Allergy Research and Education; has received a contribution to KCL Division of Asthma Allergy & Lung Biology from MRC & Asthma UK Centre; has received the BRC award to Guy's and St Thomas' NHS Foundation from the UK Department of Health through NIHR; has received support for pediatric allergy clinical trial's unit from the National Peanut Board; has received discounted Bamba peanut snack from Osem; and has stock/stock options in DBV Technologies. Dr. Suárez‐Fariñas received research funding to Mount Sinai by a grant from AllerGenis LLC. Dr. Sampson reports non‐financial support from AllerGenis LLC during the conduct of the study; grants from Immune Tolerance Network; NIAID/NIH, personal fees from N‐Fold Therapeutics, other from DBV Technologies (employee: part‐time CSO), outside the submitted work; Mount Sinai has licensed the BBEA technology to AllerGenis LLC. Dr. Sampson. serves as an unpaid Board of Directors member and advisor to AllerGenis LLC.

PY - 2023/2

Y1 - 2023/2

UR - http://www.scopus.com/inward/record.url?scp=85141965775&partnerID=8YFLogxK

U2 - 10.1111/all.15572

DO - 10.1111/all.15572

M3 - Letter

C2 - 36321870

AN - SCOPUS:85141965775

SN - 0105-4538

VL - 78

SP - 586

EP - 589

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 2

ER -